Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03762447 · ClinicalTrials.gov registry record · Phase 1
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
NCT03762447 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 138 participants.
The verdict
NCT03762447, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.
Interventions
- DRUG INCB086550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03762447
The ClinicalTrials.gov registry entry for NCT03762447 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB086550 is the first listed.
NCT03762447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03762447 about?
NCT03762447 is a clinical study titled "A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.
What is the current status of trial NCT03762447?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2018-12-10. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT03762447?
The interventions under investigation include: INCB086550 (DRUG).
Who is sponsoring clinical trial NCT03762447?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.